{"id":"early-postoperative-intraperitoneal-chemothgerapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Peritonitis or infection"},{"rate":null,"effect":"Bowel perforation"},{"rate":null,"effect":"Systemic chemotherapy toxicity"}]},"_chembl":{"chemblId":"CHEMBL2106217","moleculeType":"Small molecule","molecularWeight":"267.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach combines surgical cytoreduction with regional chemotherapy administration, allowing high local drug concentrations in the peritoneal cavity while minimizing systemic exposure. The timing immediately after surgery targets microscopic residual disease before tumor cells establish themselves, potentially improving local control and overall survival in peritoneal malignancies.","oneSentence":"Early postoperative intraperitoneal chemotherapy delivers chemotherapeutic agents directly into the peritoneal cavity immediately after surgery to target residual cancer cells and prevent peritoneal recurrence.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:27.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peritoneal carcinomatosis (various primary tumors)"},{"name":"Ovarian cancer with peritoneal involvement"},{"name":"Gastric cancer with peritoneal metastases"}]},"trialDetails":[{"nctId":"NCT02205008","phase":"PHASE3","title":"Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2012-10","conditions":"Advanced Gastric Cancer With Serosal Invasion","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Early postoperative intraperitoneal chemothgerapy","genericName":"Early postoperative intraperitoneal chemothgerapy","companyName":"Kyungpook National University Hospital","companyId":"kyungpook-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early postoperative intraperitoneal chemotherapy is a treatment approach that involves administering chemotherapy directly into the abdominal cavity after surgery to remove cancerous tissue. This treatment is being studied in clinical trials, such as NCT02205008, for its potential to treat advanced gastric cancer with serosal invasion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}